Norio Nakatsuji/X
Jun 20, 2026, 07:09
Norio Nakatsuji: LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
Norio Nakatsuji, Professor Emeritus at Kyoto University, Director General at Nakatsuji Foresight Foundation, Chief Advisor at Stem Cell and Device Lab, Inc. Bluesky, shared on X:
”LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
‘LRP5 inhibition reduced platelet activation and thrombosis with lower bleeding impact than current drugs.”’
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas LangÖ‰ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge